ReviewTissue engineering and regenerative medicine2025
Exosome Therapy: A Promising Avenue for Treating Intervertebral Disc Degeneration.
Review in Tissue engineering and regenerative medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Global trends and hotspots of macrophage-related research in intervertebral disc degeneration from 2005 to 2025: a bibliometric and visualized analysis.Frontiers in immunology · 2026Pooled it
- Therapeutic effects of stem cell-derived extracellular vesicles in animal models of intervertebral disc degeneration: a systematic review and meta-analysis of species differences and delivery strategies.Frontiers in bioengineering and biotechnology · 2026Pooled it
- Incorporation of Bone Marrow Stem Cell-Derived Exosomes into GelMA Hydrogel Effectively Attenuates Disc Degeneration in the Vertebrae of Rats.ACS omega · 2026Article
- Exosome-Based Cartilage-Targeted Delivery System: Strategies and Applications.Small science · 2026Review
- Mesenchymal stem cell and exosome-based therapies for degenerative disc disease: from mechanisms to clinical translation.Frontiers in cell and developmental biology · 2026Review
- Antioxidant biomaterials in intervertebral disc regeneration: current status and future clinical translation.Frontiers in bioengineering and biotechnology · 2026Review
- Exosome-derived ncRNAs and proteins: inflammation regulatory mechanisms and biomarker potential in spinal cord injury.Frontiers in molecular biosciences · 2026Review
- 3D bioprinted multifunctional GelMA/TMP scaffold integrated with neural stem cell-derived extracellular vesicles and neural progenitor cells for spinal cord injury repair.Journal of tissue engineeringArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe human spine relies on intervertebral discs (IVDs) for support and mobility, functioning as shock absorbers that enable friction-free movement. However, IVDs are susceptible to degeneration (IVDD) due to age, excessive strain, and genetic factors, resulting in bulging or herniation that causes pain, stiffness, and nerve compression. CURRENT TREATMENTS: Current treatments primarily focus on symptom management through medication, physical therapy, or surgery in severe cases, without addressing tissue repair. EMERGING THERAPIES: Exosome therapy has recently emerged as a promising regenerative approach for IVDD. Exosomes are small, membrane-bound vesicles released by cells, acting as messengers to transport proteins and RNA that influence recipient cell behavior. POTENTIAL AND CHALLENGES: Researchers are investigating exosomes for IVDD because they may promote disc repair and regeneration by delivering molecules that stimulate tissue recovery and carry anti-inflammatory agents to reduce inflammation and modulate pain. Engineering strategies, such as loading exosomes with therapeutic cargo or targeting molecules, can further enhance their efficacy. While exosome therapy for IVDD is still in early research stages, ongoing studies are promising, though challenges remain in optimizing isolation methods and ensuring clinical safety.
conclusionExosome-based therapies could offer a safe, effective, and minimally invasive solution for individuals affected by IVDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.